Advertisement

Topics

Latest "Cell Culture Company" News Stories

13:37 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Cell Culture Company" found in our extensive news archives from over 250 global news sources.

More Information about Cell Culture Company on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cell Culture Company for you to read. Along with our medical data and news we also list Cell Culture Company Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cell Culture Company Companies for you to search.

Showing "Cell Culture Company" News Articles 1–25 of 26,000+

Monday 18th February 2019

MSD's #Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma http://bit.ly/2S9fVLx  #oncology #cancer #Immunotherapy #pharma @Merckpic.twitter.com/kOc9pYP6sb

MSD's #Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma http://bit.ly/2S9fVLx  #oncology #cancer #Immunotherapy #pharma


Heterogeneity within classical cell types is the rule: lessons from hippocampal pyramidal neurons

Ping An Good Doctor Significantly Expands the Capacity of its Supercomputing Platform to Boost the Development of AI Healthcare Technology

SHANGHAI, Feb. 18, 2019 /PRNewswire/ -- China's leading one-stop healthcare ecosystem platform Ping An Health Medical Technology Company Limited ("Ping An Good Doctor", or the "Company", stock code: 01833.HK) has significantly expanded the capacity of its supercomputing platform. The platform now has the world's best parallel processor which can process massive data in a short ...


A Report from the Longevity Therapeutics Summit

This was the first year for the Longevity Therapeutics Summit in San Francisco, California. Ably organized by Hanson Wade, with John Lewis, CEO of Oisín Biotechnologies, as program chair, the conference focused on senolytics for senescent cell clearance, big data and AI in finding new drugs (“in silico” testing), delivery systems for therapeutics like senolytics,...

Allergic conjunctivitis pipeline has immune system response in its sights

Allergic conjunctivitis affects 10–20% of the global population and is typically treated with genericised antihistamines, mast cell stabilisers and corticosteroids....Read More... The post Allergic conjunctivitis pipeline has immune system response in its sights appeared first on Pharmaceutical Technology.

Catalent Receives P&G External Business Partner of the Year Award

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has received The Procter & Gamble Company’s (P&G) highest external business partner recognition, the External Business Partner of the Year Award. SOMERSET, N.J. (PRWEB) February 18, 2019 Catalent Pha...

Fresenius Kabi gets 510(k) clearance for Fenwal Amicus red blood cell exchange protocol

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The Fenwal Amicus RBCx system allows for the The post Fresenius Kabi gets 510(k) clearance for Fenwal Amicus red blood cell exchange protocol appeared first on Compelo Medical Devices.

Surmodics Announces Appointment of Timothy J. Arens as Chief Financial Officer

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced the appointment of Timothy J. Arens, Vice President of Corporate Development and Strategy, as the company’s new Chief Financial Officer (CFO), effective immediately. Arens was named inter...

Regenerating the field of cardiovascular cell therapy

Keytruda combo set to become "standard of care" in kidney cancer

Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care in renal cell carcinoma (RCC) thanks to impressive trial results and a price advantage over BMS’ rival drug. The combination of ant...

UCB signs research deal with King’s College London

Company and academic researchers to share one facility

Pembrolizumab, Axitinib Combo for Advanced Kidney Cancer Granted Priority Review Designation

Officials with the FDA have granted Priority Review to Merck’s supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda) for use in combination with axitinib (Inlyta, Pfizer) as first-line treatment for advanced renal cell carcinoma (RCC).

Exicure to Present at SMi’s RNA Therapeutics 2019 Conference

Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann, will present at SMi’s RNA Therapeutics 2019 Conference being held February 20-21, 2019 at the Copthorne Tara Hotel in London, UK. Dr. Giljohann’s presentation tit...

Bavencio+Inlyta combo boosts progression-free survival in advanced kidney cancer

New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that the pair “significantly extended” median progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC). Specifically, when used as a first-line treatment, the combo therapy improved median PFS by five months compared to Pfizer’s S...

MSD's #Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma http://bit.ly/2S9fVLx  #oncology #cancer #Immunotherapy #pharmapic.twitter.com/awv8SPusSH

MSD's #Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma http://bit.ly/2S9fVLx  #oncology #cancer #Immunotherapy #pharma

Cigna Plus Medical Plan now available on OneDegree Global's Online Platform

New online insurance platform provides easy access to medical protection HONG KONG, Feb. 18, 2019 /PRNewswire/ -- Cigna Corporation's (NYSE:CI) Hong Kong business today announced that its Cigna Plus Medical Plan health insurance product is now available on the new digital platform powered by OneDegree Global Limited[1] (OneDegree G...

MSD's Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma

Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal cell carcinoma (RCC) and delayed disease progression and death according to the results of a Phase 3 clinical trial. The combo outperformed Pfizer’s Sutent – the current standard of care first line treatment for advanced RCC patients. read m...

Chipscreen Biosciences Announces a Collaboration with Innovent to Evaluate Chidamide and the Combination of Sintilimab, Anti-VEGF Monoclonal Antibody IBI305 in Colorectal Cancer patients

SHENZHEN, China, Feb. 18, 2019 /PRNewswire/ -- Chipscreen Biosciences, a leading integrated Chinese biotech company specialized in discovery and development of novel small molecule pharmaceuticals with a primary focus in oncology, metabolic disease, and autoimmune diseases, announce the signing of a collaboration agreement with Innovent Biologics, Inc. (Innovent) to evaluate the safety and to...

Recce Successfully Raises AUD$1.8 million to Advance Lead Antibiotic Program

AUD$1.8m raised via placement from sophisticated and institutional investors Strengthened balance sheet to support Lead Antibiotic Program Strong support from existing and new shareholders Sydney, Australia – 18 February 2019 – Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), is pleased to announce that it has raised approximately AUD$1.8m (before costs) fro...

Emergex Secures State-of-the-Art R&D Facility and Hires a Chief Scientific Officer to Drive Development of Its Vaccines

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a novel approach to the development of vaccines for infectious diseases, today announces that it has successfully secured a state-of-the-art-research and development (R&D) facility at Milton Park, Oxfordshire. In addition, Emergex is pleased to announce the ap...

Lab Automation Now has a New Name: CyBio FeliX

The compact pipetting robot was the highlight of Analytik Jena’s trade fair appearance at this year’s SLAS, the leading conference and exhibition for laboratory automation and liquid handling in Washington DC. With its CyBio product line, Analytik Jena is one of the leading providers of lab automation and liquid handling solutions. The Company demonstrated the exceptional versatility a...

Aino Health AB (publ): Aino HealthManager deployed for global company

    18 February 2019  Aino Health's SaaS solution HealthManager has been deployed in two countries for a global company in customer service. It is a joint implementation project conducted by the client and Aino Health for 500 users. The implementation encompasses several client-tailored functionalities for automatic data transfer, adaptation to national legislation, vari...

Innovent Announces a Collaboration with Chipscreen Biosciences to Evaluate the Combination Therapy in Colorectal Cancer Patients

SUZHOU, China, Feb. 18, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality innovative medicines for the treatment of oncology, autoimmune and other major diseases, today announced the signing of a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen...

Stem Cell Umbilical Cord Blood UCB Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Stem Cell Umbilical Cord Blood UCB report provides an independent information about the Stem Cell Umbilical Cord Blood UCB industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business ove...

Customizing the Cellular Microenvironment to Improve Physiological Relevance

An interview with Marie-Charlotte Manus, discussing a new technology called PRIMO that improves the physiological relevance of cells in culture.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks